Skip to search formSkip to main contentSkip to account menu

CHR 3996

Known as: CHR-3996, CHR3996 
National Institutes of Health

Related topics

Related topics

1 relation
HDAC Inhibitor CHR-3996

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the…
Introduction: Histone deacetylase inhibitors (HDACis) have demonstrated clinical efficacy in multiple myeloma, particularly in… 
2015
2015
N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012
Purpose To identify exceptional responders among patients with advanced pancreatic cancer enrolled in first-in-man (FIM) studies… 
2010
2010
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.
2552 Background: CHR-3996, a class 1 selective HDACi inhibiting HDAC 1, 2, and 3 at low nanomolar concentrations, demonstrated… 
2010
2010
394 A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours
2009
2009
Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.
Abstract 607 Myeloma cells rely on a number of mechanisms to maintain their survival, including the silencing of genes that would… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)